-
Posted by
Two Blokes Jun 12 -
Filed in
Stock
-
7 views
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor\u00ae (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil\u00ae (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).
